They also highlight an important decrease in the expression of PD-L1 within tumor cells and myeloid cells following MRTX1257 alone and RT + MRTX1257, which is likely to reshape the tumor immune microenvironment into a pro-inflammatory, anti-tumor phenotype, contributing to the efficacy of the combination. The gene discussed is CD274; the disease is neoplasm.